risk reward incyt corp inci updat
reason chang
updat model earn
 unit state america
unless otherwis note metric base modelwar
base consensu methodolog
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
jaka perform late-stag pipelineprogress drive risk/reward
deriv price target discount cash ow analysi factor explicit
revenu project use discount rate termin growth
equal-weight believ
current level impli adequ valu
royalti cash well appropri
risk-adjust valu late-stag
pipelin believ ruxolitinib cream
andtafasitamab key area focu
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario
price either three-month one-year time view explan option probabl methodolog
jaka sale surpass upper rang
jaka sale surpass upper rang
perform ruxolitinib cream
perform ruxolitinib cream
tafasitamab success dlbcl
tafasitamab success dlbcl
jaka sale peak total
revenu ruxolitinib cream
gener peak sale
across vitiligo atop dermat
tafasitamab gener total contribut
guidanc coupl strong pipelin
guidanc coupl strong pipelin
realiz jaka sale
manag long-term guidanc
peak total revenu
approv strong uptak
ruxolitinib cream vitiligo atop
dermat aggreg peak sale
tafasitamab gener total
peak contribut
jaka sale manag
jaka sale manag
guidanc modest royalti revenu
guidanc modest royalti revenu
sale peak royalti revenu
peak iclusig sale
aggreg peak pipelin revenu
phiii data ruxolitinib steroid-refractori cgvhd
regulatori approv rux cream ad
phiii data vitiligo
clinic regulatori progress antibodi
detail jaka life cycl extens program
view explan region hierarchi
research highest favor quintil
greater pipelin realiz base case
project includ addit busi
long-term jaka sale perform
regulatori failurefor ruxolitinib cream ad
slow launch assum approv
clinic and/or regulatori failur tafasitamab
failur and/or minim success earlier-
stage program like pemigatinib
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report vikram
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import regulatori disclosur subject compani
april benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur alector inc amgen inc aprea
within last month receiv compens invest bank servic alector inc
next month expect receiv intend seek compens invest bank servic akebia
within last month receiv compens product servic invest bank servic amgen inc
within last month provid provid invest bank servic invest bank client relationship
follow compani alector inc amgen inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amgen inc beigen ltd biogen inc biomarin
 co llc make market secur alector inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
